Literature DB >> 23735192

Pharmacokinetics of intravitreally injected bevacizumab in vitrectomized eyes.

Jeeyun Ahn1, Hyuncheol Kim, Se Joon Woo, Ji Hyun Park, Sunyoung Park, Duck Jin Hwang, Kyu Hyung Park.   

Abstract

PURPOSE: To compare the pharmacokinetics (PKs) of intravitreally injected bevacizumab in vitrectomized versus nonvitrectomized control rabbit eyes.
METHODS: Twenty-five-gauge pars plana vitrectomy without lensectomy was performed in 17 right rabbit eyes (V) and 18 nonvitrectomized right rabbit eyes served as controls (C). After 1.25 mg/0.05 mL intravitreal bevacizumab (IVB) injections, eyes were enucleated at 1 h, 1, 2, 5, 14, and 30 days after the injection and immediately frozen at -80°C. Bevacizumab concentrations were determined after separation of frozen vitreous and aqueous humor (AH) compartments using indirect enzyme-linked immunosorbent assay. Bevacizumab concentration-time data were analyzed to obtain PK data.
RESULTS: Vitreous clearance of IVB consisted of 2 phases, the first fast distribution and second slow elimination phase. Clearance of IVB was accelerated in V eyes only during the first phase and not in the second phase. The vitreous concentration percent ratios between V and C eyes were 94.7% (1 h), 70.5% (1 day), 89.2% (2 days), 94.2% (5 days), 99.2% (14 days), and 79.1% (30 days). Overall vitreous half-lives were 6.99 and 7.06 days for V and C eyes, respectively (1.6-h difference).
CONCLUSION: Overall IVB PKs in rabbit eyes after vitrectomy without lensectomy are not substantially different from nonvitrectomized control eyes.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23735192      PMCID: PMC3757534          DOI: 10.1089/jop.2013.0009

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  39 in total

1.  Pharmacokinetics of intravitreal vancomycin in normal and infected rabbit eyes.

Authors:  R M Coco; M I López; J C Pastor; M J Nozal
Journal:  J Ocul Pharmacol Ther       Date:  1998-12       Impact factor: 2.671

2.  Six-month stability of bevacizumab (Avastin) binding to vascular endothelial growth factor after withdrawal into a syringe and refrigeration or freezing.

Authors:  Sophie J Bakri; Melissa R Snyder; Jose S Pulido; Colin A McCannel; William T Weiss; Ravinder J Singh
Journal:  Retina       Date:  2006 May-Jun       Impact factor: 4.256

3.  Half-life and vitreous clearance of trifluorothymidine after intravitreal injection in the rabbit eye.

Authors:  M P Pang; R V Branchflower; A T Chang; G A Peyman; H Blatt; H K Minatoya
Journal:  Can J Ophthalmol       Date:  1992-02       Impact factor: 1.882

4.  Ocular fluorescein kinetics before and after vitrectomy on swine.

Authors:  L L Knudsen; T Dissing; M N Hansen; F Nielsen-Kudsk
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2001-11       Impact factor: 3.117

5.  Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization.

Authors:  K Spilsbury; K L Garrett; W Y Shen; I J Constable; P E Rakoczy
Journal:  Am J Pathol       Date:  2000-07       Impact factor: 4.307

6.  Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization.

Authors:  Qi Zhu; Focke Ziemssen; Sigrid Henke-Fahle; Olcay Tatar; Peter Szurman; Sabine Aisenbrey; Nicole Schneiderhan-Marra; Xun Xu; Salvatore Grisanti
Journal:  Ophthalmology       Date:  2008-08-16       Impact factor: 12.079

7.  Anatomic and pharmacokinetic properties of intravitreal bevacizumab and ranibizumab after vitrectomy and lensectomy.

Authors:  John B Christoforidis; Michelle M Williams; Jillian Wang; Angela Jiang; Cedric Pratt; Mahmoud Abdel-Rasoul; George H Hinkle; Michael V Knopp
Journal:  Retina       Date:  2013-05       Impact factor: 4.256

8.  Pharmacokinetics of newer cephalosporins after subconjunctival and intravitreal injection in rabbits.

Authors:  M Barza; E Lynch; J L Baum
Journal:  Arch Ophthalmol       Date:  1993-01

9.  Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.

Authors:  L P Aiello; R L Avery; P G Arrigg; B A Keyt; H D Jampel; S T Shah; L R Pasquale; H Thieme; M A Iwamoto; J E Park
Journal:  N Engl J Med       Date:  1994-12-01       Impact factor: 91.245

10.  Intravitreal injection of methotrexate in an experimental rabbit model: determination of pharmacokinetics.

Authors:  Ebru Bener Ozkan; Altan A Ozcan; Nazan Alparslan
Journal:  Indian J Ophthalmol       Date:  2011 May-Jun       Impact factor: 1.848

View more
  23 in total

1.  Ultra-low dose of intravitreal bevacizumab in retinopathy of prematurity.

Authors:  A Şahin; Z Gürsel-Özkurt; M Şahin; F M Türkcü; A Yıldırım; H Yüksel
Journal:  Ir J Med Sci       Date:  2017-10-07       Impact factor: 1.568

2.  Intraocular pharmacokinetics of intravitreal vascular endothelial growth factor-Trap in a rabbit model.

Authors:  S J Park; J Oh; Y-K Kim; J H Park; J Y Park; H K Hong; K H Park; J-E Lee; H M Kim; J Y Chung; S J Woo
Journal:  Eye (Lond)       Date:  2015-01-16       Impact factor: 3.775

3.  Comparison of efficacy of intravitreal ranibizumab between non-vitrectomized and vitrectomized eyes with diabetic macular edema.

Authors:  Yen-Yi Chen; Pei-Ying Chen; Fang-Ting Chen; Yun-Ju Chen; Jia-Kang Wang
Journal:  Int Ophthalmol       Date:  2017-02-07       Impact factor: 2.031

4.  Outcomes of vitrectomy combined with subretinal tissue plasminogen activator injection for submacular hemorrhage associated with polypoidal choroidal vasculopathy.

Authors:  Shuhei Kimura; Yuki Morizane; Mio Morizane Hosokawa; Yusuke Shiode; Shinichiro Doi; Mika Hosogi; Atsushi Fujiwara; Toshio Okanouchi; Yasushi Inoue; Fumio Shiraga
Journal:  Jpn J Ophthalmol       Date:  2019-06-26       Impact factor: 2.447

Review 5.  Systemic and Ocular Adverse Events with Intravitreal Anti-VEGF Therapy Used in the Treatment of Diabetic Retinopathy: a Review.

Authors:  Jason A Zehden; Xavier M Mortensen; Ashvini Reddy; Alice Yang Zhang
Journal:  Curr Diab Rep       Date:  2022-09-02       Impact factor: 5.430

6.  Intravitreal bevacizumab for iatrogenic choroidal neovascular membrane following vitreoretinal surgery for retinal detachment.

Authors:  Ramya Appanraj; Hema Duraiswamy; Veerappan Saravanan; George Manayath; Narendran Venkatapathy
Journal:  Indian J Ophthalmol       Date:  2020-06       Impact factor: 1.848

7.  Estimation of Intra-vitreal Half-Lifes in the Rabbit Eye with Semi-mechanistic Equations.

Authors:  Walter Schmitt
Journal:  Pharm Res       Date:  2016-09-14       Impact factor: 4.200

8.  Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs.

Authors:  Seong Joon Ahn; Hye Kyoung Hong; Young Mi Na; Sang Jun Park; Jeeyun Ahn; Jaeseong Oh; Jae Yong Chung; Kyu Hyung Park; Se Joon Woo
Journal:  J Vis Exp       Date:  2016-07-23       Impact factor: 1.355

Review 9.  [Pharmacokinetics of intravitreally administered VEGF inhibitors].

Authors:  T U Krohne; F G Holz; C H Meyer
Journal:  Ophthalmologe       Date:  2014-02       Impact factor: 1.059

10.  Permeability of the Retina and RPE-Choroid-Sclera to Three Ophthalmic Drugs and the Associated Factors.

Authors:  Hyeong Min Kim; Hyounkoo Han; Hye Kyoung Hong; Ji Hyun Park; Kyu Hyung Park; Hyuncheol Kim; Se Joon Woo
Journal:  Pharmaceutics       Date:  2021-05-04       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.